Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Scientific microscope with visual representation of DNA helix

Trethera Awarded $2.3 Million NIH Grant to Study TRE-515 Combined with Radiation Therapy in Prostate Cancer Preclinical Models

August 26, 2025

Trethera received a $2.3M NIH grant to study TRE-515 with radiation therapy in preclinical prostate cancer models, following recent FDA Fast Track status. The research targets improved outcomes for men with metastatic castration resistant prostate cancer (mCRPC).

Read More 

Trethera Awarded $3 Million NIH Grant to Advance First-In-Class Drug, TRE-515, for the Treatment of Lupus



August 19, 2025

Trethera has been awarded a $3M NIH grant to advance TRE-515, a first-in-class drug for lupus. This novel therapy targets nucleotide metabolism, showing promise in halting disease progression with minimal side effects. Human trials are expected to follow preclinical studies.

Read More 

FDA Provides Trethera Clearance to Initiate TRE-515 Clinical Trial in Healthy Volunteers to Study Food Effect and Biomarkers



July 30, 2025

Trethera received FDA clearance to launch a clinical trial of TRE-515 in healthy volunteers, studying food effects and biomarkers. The trial supports precision dosing and expands TRE-515’s development across cancer and autoimmune diseases, reinforcing its safety and broad therapeutic potential.

Read More 

FDA Grants Fast Track Designation for TRE-515 in Combination with Radiation Therapy for the Treatment of Metastatic Castration Resistant Prostate Cancer



July 9, 2025

Trethera’s lead drug TRE-515 has received FDA Fast Track designation for advanced prostate cancer. Combined with radioligand therapy, TRE-515 aims to improve outcomes in PSMA-positive mCRPC patients, offering a novel, biomarker-driven approach to combat treatment-resistant disease.

Read More 

Trethera Secures New License, Strengthening TRE-515 Intellectual Property Portfolio and Extending Market Exclusivity to 2045



June 3, 2025

Trethera secured exclusive worldwide rights from UCLA to expand TRE-515’s use in autoimmune and inflammatory diseases. The new IP strengthens patent protection through 2045, supporting global commercialization and reinforcing TRE-515’s position as a first-in-class dCK inhibitor.

Read More 